.
This problem is particularly difficult in small atypical lesions that do not have a central scar (in the case of FNH) or are nonhemorrhagic (in the case of HA). Gadobenate dimeglumine is a hepatobiliary-specific agent, taken up to varying degrees by functioning hepatocytes and excreted in the bile. This agent is based on gadolinium and has seven unpaired electrons which give the agent their paramagnetic properties. Administrated intravenously, is initially distributed in the extracellular fluid compartment, just as classic extracellular fluid agents do, and is subsequently taken up by hepatocytes, providing the dual benefit of dynamic imaging capability as well as delayed hepatobiliary phase imaging. .
FNH lesions are composed of functioning hepatocytes and bile ducts and are, therefore, typically isointense or hyperintense relative to normal liver parenchyma in the hepatocellular phase. At hepatocellular phase imaging, HA typically appear hypointense relative to normal liver. One explanation of this phenomenon holds that HA contain functioning hepatocytes but not bile ductules, and hepatic-specific contrast agents cannot be excreted. This are the reasons why Gadobenate dimeglumine is been used widely to differentiate NFH from HA lesions. The next study presents the experience of our center using gadobenate dimeglumine imaging for characterization and differentiation between FNH and HA.
Methods and Materials.
Study Population.
This study includes all the patients who were booked in our radiology service for a liver MRI, to discriminate between FNH and HA, in which the used contrast agent was Gadobenate dimeglumine, from November 2009 to August 2012. A total of 12 patients were included (11 women, one man; mean age, 38 years ± 7,09 [± standard deviation]; range, 25-47 years). The proportion of women to men was significantly different, which reflects the greatest prevalence of these lesions among the female population.